HC Wainwright Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research report report published on Monday, Benzinga reports. The firm currently has a $7.00 target price on the stock.

Separately, Cantor Fitzgerald restated an overweight rating and set a $6.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, February 5th.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $1.16 on Monday. Lineage Cell Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $1.61. The firm has a market cap of $219.01 million, a price-to-earnings ratio of -8.92 and a beta of 1.39.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its earnings results on Thursday, March 7th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. Lineage Cell Therapeutics had a negative return on equity of 31.95% and a negative net margin of 240.20%. The company had revenue of $2.09 million during the quarter, compared to analyst estimates of $4.74 million. On average, sell-side analysts anticipate that Lineage Cell Therapeutics will post -0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Fifth Third Wealth Advisors LLC acquired a new position in shares of Lineage Cell Therapeutics during the first quarter valued at about $30,000. DCF Advisers LLC boosted its holdings in Lineage Cell Therapeutics by 14.5% during the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock worth $103,000 after purchasing an additional 12,000 shares during the last quarter. SG Americas Securities LLC grew its position in Lineage Cell Therapeutics by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock worth $34,000 after purchasing an additional 11,779 shares in the last quarter. Finally, Rathbones Group PLC bought a new position in shares of Lineage Cell Therapeutics in the third quarter valued at approximately $41,000. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.